methylprednisolone has been researched along with Minimal Disease, Residual in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (80.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bahlis, NJ; Duggan, P; Jimenez-Zepeda, VH; Lee, H; McCulloch, S; Neri, P; Tay, J | 1 |
| Bole, J; Castro, JE; Jain, S; James, DF; Kipps, TJ; Rassenti, L; Sandoval-Sus, JD | 1 |
| Ashcroft, AJ; Child, JA; DasGupta, R; Davies, FE; Drayson, MT; Jack, AS; Morgan, GJ; Owen, RG; Patmore, R; Rawstron, AC | 1 |
| Escherich, G; Hassenpflug, WA; Horstmann, MA; Janka, G; Kabisch, H; zur Stadt, U | 1 |
| Child, JA; Davies, FE; Drayson, M; Evans, PA; Forsyth, PD; Morgan, GJ; Owen, RG; Pratt, G; Rawstron, AC; Richards, SJ; Selby, PJ; Smith, GM | 1 |
5 other study(ies) available for methylprednisolone and Minimal Disease, Residual
| Article | Year |
|---|---|
The impact of COVID-19 in the management of AL amyloidosis and Immunoglobulin Deposition Disease: A single-center experience.
Topics: Aged; Alberta; Antibodies, Monoclonal; Basement Membrane; Bortezomib; COVID-19; COVID-19 Testing; Cyclophosphamide; Dexamethasone; Disease Management; Disease Susceptibility; Drug Therapy, Combination; Female; Humans; Immunoglobulin Light Chains; Immunoglobulin Light-chain Amyloidosis; Kaplan-Meier Estimate; Lenalidomide; Male; Methylprednisolone; Middle Aged; Neoplasm, Residual; Pandemics; Paraproteinemias; Precision Medicine; Retrospective Studies; SARS-CoV-2; Telemedicine | 2021 |
Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia.
Topics: Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Cohort Studies; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Maximum Tolerated Dose; Methylprednisolone; Middle Aged; Neoplasm Staging; Neoplasm, Residual; Prognosis; Rituximab; Survival Rate; Tissue Distribution | 2009 |
Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cell Count; Combined Modality Therapy; Consensus Sequence; Cyclophosphamide; Disease Progression; Disease-Free Survival; Doxorubicin; Female; Flow Cytometry; Gene Rearrangement, B-Lymphocyte, Heavy Chain; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin Heavy Chains; Life Tables; Male; Melphalan; Methylprednisolone; Middle Aged; Multiple Myeloma; Multivariate Analysis; Myeloma Proteins; Neoplasm, Residual; Neoplastic Stem Cells; Plasma Cells; Polymerase Chain Reaction; Remission Induction; Risk Factors; Sensitivity and Specificity; Survival Analysis; Transplantation, Autologous; Treatment Outcome; Vincristine | 2002 |
Amsacrine combined with etoposide and high-dose methylprednisolone as salvage therapy in acute lymphoblastic leukemia in children.
Topics: Adolescent; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Deoxycytidine; Dexamethasone; Drug Evaluation; Drug Synergism; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Infant; Leukemia-Lymphoma, Adult T-Cell; Male; Methylprednisolone; Neoplasm, Residual; Peripheral Blood Stem Cell Transplantation; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Recombinant Proteins; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Analysis; Thiotepa; Topotecan; Treatment Outcome; Vidarabine; Vinblastine | 2005 |
The impact of attaining a minimal disease state after high-dose melphalan and autologous transplantation for multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bence Jones Protein; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Electrophoresis; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Methylprednisolone; Middle Aged; Multiple Myeloma; Multivariate Analysis; Neoplasm, Residual; Survival Rate; Transplantation Conditioning; Transplantation, Autologous; Vincristine | 2001 |